Topic · 2 reports

Marketing Fraud

RegulationWatch reporting on marketing fraud matters involving US pharmaceutical manufacturers, PBMs and healthcare companies, newest first.

  1. Marketing Fraud

    Veloxis pays over $46 million and enters deferred prosecution over kickbacks

    Veloxis Pharmaceuticals Inc. has agreed to pay more than $46 million to resolve criminal and civil allegations that it paid kickbacks to boost prescriptions of its kidney transplant drug Envarsus XR. The resolution includes a deferred prosecution agreement, a $34.45 million False Claims Act settlement and a $1.55 million Sunshine Act penalty — the largest since the law's passage.

  2. Marketing Fraud

    Takeda pays $13.6 million over Trintellix speaker program kickback allegations

    Takeda Pharmaceuticals U.S.A. Inc. has agreed to pay $13,670,921 to resolve Department of Justice allegations that it paid kickbacks to healthcare providers, in the form of speaker honoraria and high-end meals, to induce prescriptions of the antidepressant Trintellix. The government alleged the conduct caused false claims to Medicare and other federal programmes.